Amneal Pharmaceuticals (AMRX) Short term Debt (2017 - 2026)

Amneal Pharmaceuticals' Short term Debt history runs 10 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Short term Debt fell 80.5% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (down 80.5% YoY), while the FY2025 annual figure was $6.8 million, down 96.98% from the prior year.
• Short term Debt was $6.2 million for Q1 2026 at Amneal Pharmaceuticals, down from $6.8 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $290.0 million in Q2 2025 to a low of $6.2 million in Q1 2026.
• Historically, Short term Debt has averaged $82.3 million across 5 years, with a median of $34.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Short term Debt soared 1113.56% in 2024, then plunged 96.98% in 2025.
• A 5-year view of Short term Debt shows it stood at $60.0 million in 2022, then plunged by 43.12% to $34.1 million in 2023, then surged by 557.03% to $224.2 million in 2024, then slumped by 96.98% to $6.8 million in 2025, then dropped by 8.3% to $6.2 million in 2026.
• The last three Short term Debt figures came in at $6.2 million (Q1 2026), $6.8 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.